Literature DB >> 26990920

Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial.

Hitesh C Patel1, Stuart D Rosen2, Carl Hayward1, Vassilios Vassiliou1, Gillian C Smith1, Ricardo R Wage1, James Bailey1, Ronak Rajani3, Alistair C Lindsay1, Dudley J Pennell1, S Richard Underwood1, Sanjay K Prasad1, Raad Mohiaddin1, J Simon R Gibbs4, Alexander R Lyon1, Carlo Di Mario1.   

Abstract

AIM: Heart failure with preserved ejection fraction (HFpEF) is associated with increased sympathetic nervous system (SNS) tone. Attenuating the SNS with renal denervation (RDT) might be helpful and there are no data currently in humans with HFpEF. METHODS AND
RESULTS: In this single-centre, randomized, open-controlled study we included 25 patients with HFpEF [preserved left ventricular (LV) ejection fraction, left atrial (LA) dilatation or LV hypertrophy and raised B-type natriuretic peptide (BNP) or echocardiographic assessment of filling pressures]. Patients were randomized (2:1) to RDT with the Symplicity™ catheter or continuing medical therapy. The primary success criterion was not met in that there were no differences between groups at 12 months for Minnesota Living with Heart Failure Questionnaire score, peak oxygen uptake (VO2 ) on exercise, BNP, E/e', LA volume index or LV mass index. A greater proportion of patients improved at 3 months in the RDT group with respect to VO2 peak (56% vs. 13%, P = 0.025) and E/e' (31% vs. 13%, P = 0.04). Change in estimated glomerular filtration rate was comparable between groups. Two patients required plain balloon angioplasty during the RDT procedure to treat renal artery wall oedema.
CONCLUSION: This study was terminated early because of difficulties in recruitment and was underpowered to detect whether RD improved the endpoints of quality of life, exercise function, biomarkers, and left heart remodelling. The procedure was safe in patients with HFpEF, although two patients did require intraprocedure renal artery dilatation.
© 2016 The Authors European Journal of Heart Failure © 2016 European Society of Cardiology.

Entities:  

Keywords:  Heart failure with preserved ejection fraction; Meta-iodo-benzyl-guanidine; Noradrenaline; Renal denervation; Sympathetic nervous system

Mesh:

Substances:

Year:  2016        PMID: 26990920     DOI: 10.1002/ejhf.502

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  20 in total

1.  Heart failure with mid-range ejection fraction and with preserved ejection fraction.

Authors:  J Petutschnigg; F Edelmann
Journal:  Herz       Date:  2018-08       Impact factor: 1.443

Review 2.  Heart failure with preserved ejection fraction.

Authors:  Andrew R Harper; Hitesh C Patel; Alexander R Lyon
Journal:  Clin Med (Lond)       Date:  2018-04-01       Impact factor: 2.659

3.  Renal Denervation to Treat Heart Failure.

Authors:  Thomas E Sharp; David J Lefer
Journal:  Annu Rev Physiol       Date:  2020-10-19       Impact factor: 19.318

Review 4.  Autonomic Modulation With Baroreflex Activation Therapy in Heart Failure.

Authors:  Edoardo Gronda; Emilio Vanoli
Journal:  Curr Heart Fail Rep       Date:  2016-12

Review 5.  Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions.

Authors:  Bharathi Upadhya; Mark J Haykowsky; Dalane W Kitzman
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

6.  [Heart failure with preserved left ventricular ejection fraction].

Authors:  Johannes Petutschnigg; Frank Edelmann
Journal:  Internist (Berl)       Date:  2019-09       Impact factor: 0.743

Review 7.  Therapeutic Approaches in Heart Failure with Preserved Ejection Fraction (HFpEF) in Children: Present and Future.

Authors:  Bibhuti B Das
Journal:  Paediatr Drugs       Date:  2022-05-02       Impact factor: 3.022

Review 8.  Baroreflex Activation Therapy in Congestive Heart Failure: Novel Findings and Future Insights.

Authors:  Guido Grassi; GianMaria Brambilla; Daniela Prata Pizzalla; Gino Seravalle
Journal:  Curr Hypertens Rep       Date:  2016-08       Impact factor: 5.369

9.  Percutaneous renal artery denervation in patients with chronic systolic heart failure: A randomized controlled trial.

Authors:  Jun-Qing Gao; Wei Yang; Zong-Jun Liu
Journal:  Cardiol J       Date:  2018-04-03       Impact factor: 2.737

Review 10.  Heart failure with preserved ejection fraction: current management and future strategies : Expert opinion on the behalf of the Nucleus of the "Heart Failure Working Group" of the German Society of Cardiology (DKG).

Authors:  Carsten Tschöpe; Christoph Birner; Michael Böhm; Oliver Bruder; Stefan Frantz; Andreas Luchner; Lars Maier; Stefan Störk; Behrouz Kherad; Ulrich Laufs
Journal:  Clin Res Cardiol       Date:  2017-10-10       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.